This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus
by Zacks Equity Research
CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.
OMCLNegative Net Change CVNegative Net Change SDGRPositive Net Change CCLDNegative Net Change
medical medical-devices
INBS Stock Surges 132.4% on New Manufacturing Partnership
by Zacks Equity Research
Intelligent Bio Solutions' stock jumps after a new manufacturing partnership aimed at cutting costs, boosting margins and scaling production ahead of U.S. expansion.
BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change INBSNegative Net Change
medical medical-devices
Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio
by Zacks Equity Research
MD is positioned for growth on stronger collections, payer mix and acquisitions, as shares jump 55.2% in six months, beating the industry's 6.7% gain.
MDNegative Net Change ANIPNegative Net Change CRMDPositive Net Change COLLNegative Net Change
medical
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
by Zacks Equity Research
CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.
RHHBYNegative Net Change CORTPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
medical
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
by Ekta Bagri
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
REGNPositive Net Change ABBVPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III
by Sundeep Ganoria
Viking Therapeutics' obesity drug VK2735 is racing through phase III, with one pivotal study fully enrolled just months after launch.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Implied Volatility Surging for Corcept Stock Options
by Zacks Equity Research
Investors need to pay close attention to CORT stock based on the movements in the options market lately.
CORTPositive Net Change
medical
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
by Zacks Equity Research
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Are Options Traders Betting on a Big Move in Delcath Systems Stock?
by Zacks Equity Research
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.
DCTHNegative Net Change
medical
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
INGN gains momentum from rising POC demand, new product launches and strong Q3 sales, even as competition and forex swings temper near-term growth.
ISRGNegative Net Change INGNNegative Net Change MEDPPositive Net Change SGHTNegative Net Change
medical medical-devices
Looking for Income? 5 Stocks That Recently Raised Dividends
by Santanu Roy
ENSG, IVR, ABM, BEN and NWFL recently raised dividend payouts, offering income-focused investors options as markets balance AI optimism and Fed caution.
BENNegative Net Change ABMPositive Net Change IVRPositive Net Change ENSGNegative Net Change NWFLNegative Net Change
business-services finance medical reit
Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
by Sundeep Ganoria
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
BIIBPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Is This the Right Time to Add PBH Stock to Your Portfolio?
by Zacks Equity Research
Prestige Consumer Healthcare benefits from e-commerce momentum, acquisitions and solid solvency, even as inflation and tariff costs pose near-term risks.
ILMNPositive Net Change PBHNegative Net Change PODDNegative Net Change BTSGPositive Net Change
medical
Is it the Right Time to Add Insulet Stock to Your Portfolio?
by Zacks Equity Research
PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.
DGXPositive Net Change PODDNegative Net Change PAHCNegative Net Change BTSGPositive Net Change
medical medical-devices
Company News for Jan 2, 2026
by Zacks Equity Research
Companies In The Article Are NKE,TSM,CORT,MSFT,NVDA
MSFTNegative Net Change NKENegative Net Change NVDAPositive Net Change TSMPositive Net Change CORTPositive Net Change
computers medical retail
Best Growth Stocks to Buy for January 2nd
by Zacks Equity Research
RNR, GLDD and PAHC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 2, 2026.
RNRNegative Net Change GLDDPositive Net Change PAHCNegative Net Change
construction finance medical
Why You Should Add Encompass Health to Your Portfolio Now
by Zacks Equity Research
EHC's expanding rehabilitation hospital network, strong cash flow and growing patient volumes reinforce its market position.
MDNegative Net Change ANIPNegative Net Change COLLNegative Net Change EHCPositive Net Change
medical
Here's Why You Should Retain Community Health Stock for Now
by Zacks Equity Research
CYH shows improving occupancy, targeted acquisitions and divestitures and a rising cash flow outlook, making the hospital operator worth holding for now.
CYHNegative Net Change ANIPNegative Net Change CRMDPositive Net Change COLLNegative Net Change
artificial-intelligence medical
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
by Zacks Equity Research
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.
BSXNegative Net Change ISRGNegative Net Change HQYNegative Net Change MEDPPositive Net Change
medical medical-devices
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
by Zacks Equity Research
CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.
BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change CODXPositive Net Change
medical medical-devices
KRMD Submits 510(k) to Use FreedomEDGE System With Oncology Biologic
by Zacks Equity Research
KORU Medical filed a 510(k) to use FreedomEDGE for subcutaneous PHESGO delivery, expanding into oncology and simplifying breast cancer care.
OMCLNegative Net Change KRMDNegative Net Change SDGRPositive Net Change CCLDNegative Net Change
medical medical-devices
Riding the Marijuana Reclassification Wave: 3 Stocks to Watch in 2026
by Sundeep Ganoria
Marijuana's potential move to Schedule III could reshape cannabis economics, putting CRON, VFF and TLRY in focus for 2026 investors.
CRONPositive Net Change TLRYPositive Net Change VFFPositive Net Change
marijuana medical
BAYRY's 2025 Revival: Will the Momentum Continue in 2026?
by Zacks Equity Research
BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.
REGNPositive Net Change JNJPositive Net Change BAYRYPositive Net Change
cell-therapy medical pharmaceuticals
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains
by Zacks Equity Research
Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.
NVOPositive Net Change VNDANegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
ISRG Sees 91% SP Growth: A Turning Point for Single-Port Surgery?
by Indrajit Bandyopadhyay
ISRG's single-port platform posts 91% procedure growth, led by Korea, with U.S. momentum building as new tools and indications expand adoption.
SYKNegative Net Change ISRGNegative Net Change GMEDNegative Net Change
medical medical-devices